NEW YORK and LONDON, December 5th, 2016
– Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing-
-PAS-Coversin pre-clinical data supports once weekly dosing-
-Phase II PNH patients identified with data expected 1Q17-
-Eculizumab resistant PNH patient treated for over 9 months with Coversin-
-New pipeline of tick derived and engineered proteins-
-Coversin engineered protein targeting neuromuscular junction for myasthenia gravis-
-Proteins targeting two additional pathways as well as second complement inhibitor-
NEW YORK and LONDON, December 5th, 2016 (GLOBE NEWSWIRE) — Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced several corporate updates that were discussed during an Analyst & Investor Symposium held during the 58th American Society of Hematology meeting. The corporate presentation is available at https://akaritx.com/event/ash-analyst-investor-symposium/.
